0001736297-25-000147
SEC filingRevenue surged 104% YoY to $230.6M in Q3 2025, driven by Aries, Scorpio, and Taurus demand, while gross margin contracted 150bps due to product mix shift to hardware modules.
For the three months ended September 30, 2025, total revenue reached $230.6 million, a 104% increase from $113.1 million in the same period in 2024. The growth was driven by higher unit shipments across all major product families (Aries, Scorpio, and Taurus) and an increase in average selling prices due to an expanded mix of hardware modules and Scorpio products. Cost of revenue increased 117% to $54.8 million, outpacing revenue growth, resulting in a gross profit of $175.8 million (up 100% YoY). Gross margin contracted 150 basis points to 76.2% from 77.7% in Q3 2024, primarily due to the product mix shift toward hardware modules, which typically carry lower margins than ICs.
Operating expenses increased 24% to $120.4 million, driven by a 79% increase in headcount and higher R&D spending, partially offset by a $5.1 million decrease in non-cash stock-based compensation. Research and development expense rose 56% to $78.9 million, sales and marketing declined 17% to $19.4 million, and general and administrative decreased 3% to $22.1 million. As a result, GAAP operating income improved to $55.4 million from an operating loss of $8.9 million in the prior year. Net income reached $91.1 million versus a net loss of $7.6 million, aided by a $24.3 million income tax benefit primarily from excess tax benefits related to equity compensation.
For the nine months ended September 30, 2025, revenue totaled $581.9 million (up 128% YoY), gross margin was 75.7% (down 200 bps), and net income was $174.2 million versus a loss of $108.1 million in the prior period.
The company does not report segment-level financials. However, the MD&A highlights that growth was broad-based across Aries PCIe/CXL retimers and cable modules, Taurus Ethernet cable modules, and Scorpio smart fabric switches. The revenue mix shifted toward hardware modules, which contributed to the gross margin decline but also led to higher absolute gross profit. Management noted that average selling prices improved due to the mix of Scorpio products and modules, indicating strong demand for higher-value solutions.
The MD&A does not provide explicit forward guidance. However, management expressed confidence in the company's Intelligent Connectivity Platform and its ability to address data, network, and memory bottlenecks in cloud and AI infrastructure. The strong revenue growth and improved cash flow from operations ($224.0 million for nine months) suggest continued investment in R&D and headcount to scale operations. The company also highlighted material cash requirements related to operating leases and purchase commitments, but believes its $1.13 billion in cash, cash equivalents, and marketable securities is sufficient for at least the next 12 months.
Astera Labs maintains a robust liquidity position with $140.4M in cash and cash equivalents and $994.0M in marketable securities as of September 30, 2025, totaling $1.13B. The marketable securities portfolio is primarily invested in corporate debt securities ($749.4M) and U.S. treasury/agency securities ($227.0M), with no material impairments. Total assets stood at $1.40B, driven by growth in current assets. Shareholders' equity increased to $1.27B from $964.8M at year-end 2024, reflecting net income of $174.2M and $118.7M in stock-based compensation. The company has no debt, with total liabilities of $129.5M mainly comprising accounts payable and accrued expenses.
As of September 30, 2025, Astera Labs has total purchase commitments of $59.6M, primarily related to wafer manufacturing subcontractors, software licenses, and cloud services. The commitments are scheduled as follows: $8.8M in the remainder of 2025, $21.0M in 2026, $22.4M in 2027, $7.1M in 2028, and $0.3M in 2029. Operating lease liabilities total $31.3M, with the new San Jose headquarters lease (7.5-year term) contributing $21.2M in ROU assets. No material legal contingencies are disclosed.
Astera Labs did not repurchase shares or pay dividends during the period. The company continues to invest in growth, with capital expenditures of $18.9M for the nine months ended September 30, 2025 (3.25% of revenue), primarily for production equipment and construction in progress. No debt was issued or repaid. Stock-based compensation totaled $118.7M, reflecting ongoing equity incentive programs.
Astera Labs operates as a single reporting segment. Geographic revenue distribution for the nine months ended September 30, 2025 shows Singapore $193.5M (33%), China $181.1M (31%), Taiwan $171.1M (29%), United States $17.6M (3%), and other $18.7M (3%). Customer concentration is notable: Customer A represented 25% of revenue, Customer B 21%, Customer C 15%, Customer D 14%, and Customer E 10%. No single customer exceeded 22% of accounts receivable.
CFO of $224M significantly exceeded net income of $174M, driven by non-cash charges like stock-based compensation ($119M) and depreciation ($4M). The cash conversion ratio (CFO/Net Income) was 1.29x, indicating high earnings quality. Capex intensity remained low at 8.4% of CFO, suggesting asset-light operations. Investing activities were dominated by net purchases of marketable securities ($149M), reducing cash available. Financing provided only $6M, mostly from stock option exercises, contrasting with prior year's $650M IPO proceeds. Working capital changes consumed $73M, primarily from prepaid expenses and other assets ($57M). No share repurchases or dividends were reported.